Ramucirumab

證據等級: L5

預測適應症: 10 個

Ramucirumab: From Solid Tumor Oncology to Uterine Ligament Adenocarcinoma

One-Sentence Summary

Ramucirumab is an anti-VEGFR2 monoclonal antibody used in solid tumor oncology; its specific original indication is not captured in this evidence pack. The TxGNN model predicts it may be effective for Uterine Ligament Adenocarcinoma, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests entirely on knowledge-graph association strength and a class-level anti-angiogenic mechanism hypothesis.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (original_indications field empty; DrugBank extraction incomplete)
Predicted New Indication	Uterine Ligament Adenocarcinoma
TxGNN Prediction Score	99.95%
Evidence Level	L5
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in structured form (original_moa is a data gap). Based on the rationale captured for this candidate, ramucirumab is an anti-VEGFR2 monoclonal antibody that mechanistically inhibits angiogenesis in solid tumors, giving it theoretical broad-spectrum potential against highly vascularized malignancies — including gynecologic cancers.

This is, however, a class-level extrapolation, not a disease-specific finding. Uterine ligament adenocarcinoma is a rare histological subtype, and no direct clinical, preclinical, or observational data linking ramucirumab to this indication exists in any of the queried sources (ClinicalTrials.gov, ICTRP, PubMed all returned zero results). The extremely high TxGNN score (99.95%) reflects the strength of the model's learned graph association, not clinical validation — the same pattern repeats across all 10 top-ranked predictions for this drug, which are all rare uterine/cervical adenocarcinoma subtypes clustered together in the knowledge graph, each equally lacking supporting evidence.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Ramucirumab has no marketing authorizations in Finland (market status: not marketed, 0 licenses on file).

Cytotoxicity

Ramucirumab is an antineoplastic agent (anti-VEGFR2 monoclonal antibody used in solid tumor oncology).

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-VEGFR2 monoclonal antibody / anti-angiogenic agent)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate cannot yet advance past the S0 (model-prediction-only) stage. The TFDA/regulatory package insert data gap is classified Blocking — it explicitly prevents entry into S1 safety pre-evaluation — and none of the top 10 predicted indications (all rare uterine/cervical adenocarcinoma subtypes, ranked 814–978 by TxGNN) have any supporting clinical trial or literature evidence.

To proceed, the following is needed:

Original indication and approved-label data for ramucirumab (currently missing from evidence pack)
TFDA/Fimea package insert (warnings, contraindications) — Blocking gap, required before any S1 safety review
Confirmed mechanism of action detail via DrugBank API (High severity gap)
At minimum, preclinical or mechanistic studies specific to gynecologic malignancies before this candidate can move beyond model-prediction-only status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.